Business UpdateJun 30, 2026, 08:02 AM
Quince Therapeutics Forms Scientific Advisory Board for LAM-001 Development
AI Summary
Quince Therapeutics, Inc. announced the formation of a Scientific Advisory Board (SAB) comprising internationally recognized experts in pulmonary medicine. The SAB will guide the development of LAM-001, an inhaled rapamycin formulation, across multiple pulmonary indications including PH-ILD, BOS, and SAPH. The company plans to initiate a Phase 2b trial for LAM-001 in PH-ILD in mid-2026 and a Phase 2 study in SAPH in late 2026, while data from the fully enrolled Phase 2 BOS trial is expected in Q1 2027.
Key Highlights
- Quince Therapeutics formed a Scientific Advisory Board (SAB) of leading clinicians.
- SAB will support LAM-001 development for PH-ILD, BOS, and SAPH.
- LAM-001 is an inhaled rapamycin (mTOR inhibitor) designed for pulmonary delivery.
- Phase 2a data for LAM-001 in PH-ILD was presented in May 2026.
- Phase 2b PH-ILD trial to start mid-2026, with data anticipated in Q1 2028.
- Phase 2 BOS trial is fully enrolled, with data anticipated in Q1 2027.
- Phase 2 SAPH trial is planned to initiate in late 2026.
- PH-ILD affects ~86K patients in US, BOS ~17K in US, SAPH ~60K in US & EU.
Price Impact
More from QNCX